Nasdaq Welcomes Athenex, Inc. (Nasdaq: ATNX) to The Nasdaq Stock Market
June 14 2017 - 11:45AM
Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer, visited the Nasdaq
MarketSite in Times Square today in celebration of its initial
public offering (IPO) on The Nasdaq Stock Market.
Athenex aims to improve the lives of cancer patients by creating
more effective, safer and tolerable treatments. Athenex has
generated its clinical product candidates through its Orascovery
and Src Kinase Inhibition research platforms, which are based on
the Company’s understanding of human absorption biology and novel
approaches to inhibiting kinase activity, respectively.
“We are pleased to have successfully completed our Initial
Public Offering on Nasdaq, an exciting milestone in our Company’s
growth. We remain focused on developing and commercializing safe
and efficacious oncology focused medication and continuing to
advance our pipeline candidates through clinical trials,” said
Johnson Y.N. Lau, Chief Executive Officer and Board Chairman,
Athenex.
“Nasdaq continues to be the listing venue of choice for
innovators in both healthcare and technology, two of the fastest
changing industries. We welcome Athenex and look forward to
supporting the company as it advances novel therapies for cancer
treatment and improving health outcomes,” said Nelson Griggs,
Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational
and educational purposes only, and nothing contained herein should
be construed as investment advice, either on behalf of a particular
security or an overall investment strategy. Information about the
company is provided by the company or comes from the company’s
public filings and is not independently verified by Nasdaq.
Neither Nasdaq nor any of its affiliates makes any recommendation
to buy or sell any security or any representation about the
financial condition of any company. Statements regarding
Nasdaq-listed companies are not guarantees of future performance.
Actual results may differ materially from those expressed or
implied. Past performance is not indicative of future results.
Investors should undertake their own due diligence and carefully
evaluate companies before investing. ADVICE FROM A SECURITIES
PROFESSIONAL IS STRONGLY ADVISED.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 89
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to 3,800 total listings with a market
value of $11.0 trillion. To learn more, visit:
http://business.nasdaq.com.
- NDAQG -
Media Relations Contacts:
Stephanie Lowenthal
(646) 441-5073
Stephanie.Lowenthal@nasdaq.com
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2024 to May 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From May 2023 to May 2024